Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
5714-73-8
Molecular formula
C15H21N5O3
Molecular weight
319.36 g/mol
Drug class
Urinary antisepticmethenamine salt of hippuric acid
Mechanism of action
In acidic urine, methenamine is hydrolysed to formaldehyde, which exerts nonspecific antibacterial activity within the urinary tract. Hippuric acid contributes urinary acidification; effectiveness depends on maintaining sufficiently acidic urine.
Indications / reported uses
Prophylaxis or suppressive treatment of recurrent urinary-tract infections after the active infection has been eradicated by appropriate antibacterial therapy; not for treatment of acute pyelonephritis or systemic infection
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Methenamine Hippurate Environmental Risk Assessment (ERA) (the Methenamine Hippurate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.